Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes
Merlin C. Thomas(Monash University), Per‐Henrik Groop(University of Helsinki), Mats Rönnback(Helsinki University Hospital), Carol Forsblom(University of Helsinki), Stephen Thomas(Helsinki University Hospital), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa), Mark E. Cooper(Australian Regenerative Medicine Institute), Vashti Mills(Helsinki University Hospital), Giancarlo Viberti(Guy's Hospital), Milla Rosengård‐Bärlund
Cited by 80
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k